Cancer therapy sensitizer

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 5/10 (2006.01) A01N 61/00 (2006.01) A61K 6/00 (2006.01) A61K 31/00 (2006.01) A61K 31/7088 (2006.01) A61K 35/12 (2006.01) A61K 38/17 (2006.01) A61K 48/00 (2006.01) A61P 35/00 (2006.01) C07K 1/00 (2006.01) C12Q 1/68 (2006.01) G01N 33/50 (2006.01)

Patent

CA 2513251

The present invention relates to compositions and methods for sensitizing cancer therapy. The invention provides such compositions comprising a SPARC family polypeptide or polynucleotide, as well as recombinant cells containing a SPARC family polypeptide or polynucleotide. The compositions and methods of the invention are useful in in vitro study of cancer therapy resistance, as well as ex vivo and in vivo therapy of cancer.

La présente invention concerne des compositions et des méthodes permettant de rendre sensible une thérapie de cancer. Cette invention a trait à ces compositions contenant un polypeptide ou un polynucléotide de la famille SPARC, ainsi qu'à des cellules recombinantes renfermant un polypeptide ou un polynucléotide de la famille SPARC. Lesdites compositions et méthodes sont utilisées dans une étude in vitro de résistance d'une thérapie de cancer, ainsi que dans une thérapie de cancer ex vivo et in vivo.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Cancer therapy sensitizer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer therapy sensitizer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer therapy sensitizer will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1899700

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.